Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

487
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
487
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

517
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
517

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral blood immunoglobulin A level is independently negatively correlated with renal involvement in newly diagnosed childhood systemic lupus erythematosus: a single-center cross-sectional study based on 380 pediatric lupus nephritis patients in southwest China.

Clinical rheumatology·2026
Same author

MOF-derived carbon membranes for catalytic ozonation: Site-dependent evolution of surface atomic oxygen enables efficient water purification.

Water research·2026
Same author

The effects of generative AI on foreign language emotions: A meta-analysis.

Acta psychologica·2026
Same author

Mixing Ratio and Relative Humidity Govern Dimethylamine Uptake on Ammonium Sulfate-Glyoxylic Acid Aerosols: Kinetics and Brown Carbon Formation.

Environmental science & technology·2026
Same author

Nasogastric vs. nasojejunal feeding in stroke patients under a DRG payment system: balancing clinical benefits and economic costs.

Health economics review·2026
Same author

Population Pharmacokinetics and Clinical Application of Vancomycin in Critically Ill Adults: A NONMEM-Based Review.

Drug design, development and therapy·2026

Related Experiment Video

Updated: Jan 10, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.2K

Moderate tea consumption and dementia-related neuroimaging markers.

Ting Jin1,2,3, Dongwei Lu4, Jiyu Chen5

  • 1Department of Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Frontiers in Neurology
|November 27, 2025
PubMed
Summary

Moderate tea consumption is linked to better brain health and a lower risk of dementia. Drinking 4-5 cups daily showed the most significant reduction in dementia risk, supporting tea

Keywords:
UK Biobankcognitiondementianeuroimagingtea consumption

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.7K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.2K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.7K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

Area of Science:

  • Neuroscience
  • Public Health
  • Nutritional Psychiatry

Background:

  • Tea consumption is a global habit with potential health benefits.
  • Previous studies suggest a link between tea and reduced dementia risk.
  • The impact of tea on dementia-related neuroimaging markers is not well understood.

Purpose of the Study:

  • To investigate the association between tea consumption and brain imaging markers.
  • To examine the relationship between tea intake and dementia risk.
  • To explore the dose-response effect of tea on brain health and dementia incidence.

Main Methods:

  • Analysis of 438,078 dementia-free UK Biobank participants.
  • Utilized linear regression for brain imaging analysis (38,584 participants).
  • Employed Cox proportional hazards and logistic regression for dementia risk and cognitive decline, adjusting for covariates.

Main Results:

  • Moderate tea intake correlated with increased gray matter volume in specific brain regions.
  • Consuming 6-7 cups daily was linked to reduced white matter hyperintensity (WMH) and anterior cingulate cortex (ACC) volumes.
  • Optimal dementia risk reduction observed at 4-5 cups daily, with no association found for cognitive decline.

Conclusions:

  • Moderate tea consumption is associated with improved brain structure and reduced dementia risk.
  • Findings suggest a neuroprotective effect of moderate tea intake.
  • This study highlights the potential of moderate tea consumption in dementia prevention strategies.